TrialBlood advances2026

A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase 1/2 trials.

Wei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.